Cedara Software Corp., which is a division of Merge Technologies Inc., this week announced that Cedara B-CAD, a Computer Aided Detection (CAD) product for breast ultrasound, has received 510(k) clearance from the US Food & Drug Administration (FDA), said Cedara.

Cedara B-CAD will soon be commercially available in the United States.  B-CAD was developed by Toronto based Medipattern Corporation (TSX-V: MKI), a company focused on medical pattern recognition and brought to market by Cedara Software Corp. through it's Technology Partnership Program.